Oncolytic Immunotherapy: Q&A With OncoMyx Therapeutics CEO Steve Potts

< back

In advance of ASCO, Jonathan Faison of Seeking Alpha chatted with OncoMyx’s CEO Steve Potts about oncolytic immunotherapy, myxoma virus differentiators, pros and cons of intratumoral vs IV delivery, and what data in the field has peeked his interest.

To read the full article, click here.